Valeant Pharmaceuticals is in Congress’ crosshairs again — with one lawmaker demanding the drugmaker turn over documents related to an investigation into the company’s relationship with Philidor Rx Services.
Striking an accusatory tone, Rep. Elijah Cummings (D-Md.), the ranking member of the House Oversight Committee, called on Valeant to turn over any communications related to a recently concluded investigation by an ad hoc committee created by the company, such as presentations to the board and interview transcripts.
Valeant formed the committee in October in response to accusations that Philidor was a “phantom” mail-order pharmacy secretly controlled by the drugmaker, leading to accusations that Philidor changed generic prescriptions from doctors to higher-priced branded prescriptions. Valeant cut ties with Philidor a few days later over the scandal.